Oleic Acid
CAS 112-80-1
Oleic Acid (CAS 112-80-1) is a Phase 2 pharmaceutical compound with 16 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | GI50 | 184165.51508474577 nM | 59 | - |
| - | AC50 | 25778.55625 nM | 32 | - |
| - | Potency | 31230.013333333332 nM | 29 | - |
| - | IC50 | 25008.032631578946 nM | 18 | - |
| - | MIC | 257.7142857142857 ug.mL-1 | 14 | - |
| - | Ki | 4716.142857142857 nM | 7 | - |
| - | EC50 | 46982 nM | 5 | - |
| - | MIC | 50 ug | 5 | - |
| - | Kd | 15275 nM | 4 | - |
| Fatty-acid amide hydrolase 1 Enzyme |
Ki | 5.22 | - | Homo sapiens |
| Aromatase Enzyme |
IC50 | 4.49 | - | Homo sapiens |
| Peroxisome proliferator-activated receptor alpha Nuclear hormone receptor |
IC50 | 6.22 | - | Homo sapiens |
| Peroxisome proliferator-activated receptor gamma Nuclear hormone receptor |
IC50 | 5.39 | - | Homo sapiens |
| Tyrosine-protein phosphatase non-receptor type 1 Enzyme |
IC50 | 5.21 | - | Homo sapiens |
| Fatty acid-binding protein, adipocyte Cytosolic other |
Ki | 6.73 | - | Homo sapiens |
| DNA topoisomerase 1 Enzyme |
IC50 | 4.51 | - | Homo sapiens |
| Telomerase reverse transcriptase Enzyme |
IC50 | 5.07 | - | Homo sapiens |
| Fatty acid-binding protein, epidermal Cytosolic other |
Ki | 6.61 | - | Homo sapiens |
| Peroxisome proliferator-activated receptor delta Nuclear hormone receptor |
IC50 | 5.28 | - | Homo sapiens |
| Free fatty acid receptor 1 GPCR |
EC50 | 5.7 | - | Homo sapiens |
| Fatty acid-binding protein, liver Unclassified |
Kd | 6.7 | - | Homo sapiens |
| Fatty acid-binding protein, liver Unclassified |
Ki | 6.74 | - | Rattus norvegicus |
| Seed linoleate 13S-lipoxygenase-1 Enzyme |
Ki | 4.66 | - | Glycine max |
| Tissue factor Membrane receptor |
IC50 | 4.1 | - | Homo sapiens |
| Free fatty acid receptor 4 GPCR |
EC50 | 4.7 | - | Homo sapiens |
| Nuclear receptor subfamily 4 group A member 2 Nuclear other |
Kd | 4.3 | - | Homo sapiens |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| FFA1 receptor FFAR1 |
Full agonist | 3.9000000953674316 pEC50 | 12496284|12565875|12629551 |
| FFA4 receptor FFAR4 |
Full agonist | 4.699999809265137 pEC50 | 22282525 |
| PLD2 PLD2 |
Activation | - | 12374567 |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| OLEIC ACID | 7631 | SU | MTHSPL |
| Oleic Acid | 7631 | SU | MTHSPL |
| oleic acid | 7631 | SU | MTHSPL |
| oleic acid | 7631 | PIN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Oleic Acid used for in pharmaceutical contexts?
Oleic Acid (CAS 112-80-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Oleic Acid?
No adverse-event association or SIDER side-effect rows are rendered for Oleic Acid in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Oleic Acid also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Oleic Acid with EU status "permitted".
What clinical phase is Oleic Acid in?
Oleic Acid is rendered with ChEMBL max phase 2.
What bioactivity targets are documented for Oleic Acid?
Oleic Acid has 26 bioactivity rows in this page query. Rendered target entries include Fatty-acid amide hydrolase 1, Aromatase, Peroxisome proliferator-activated receptor alpha, Peroxisome proliferator-activated receptor gamma, Tyrosine-protein phosphatase non-receptor type 1.